Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triamcinolone Acetonide for OME Prevention in NPC
NCT07189572Phase 3Not yet recruiting
- Start
- Oct 2025
- Primary completion
- Aug 2027
- Modality
- Orthosteric Ligands
01
Overview
Phase 3, randomised, double-blind trial in otitis media with effusion (OME) comparing Triamcinolone Acetonide with Placebo (2 arms). Primary endpoint: Incidence of Otitis Media with Effusion. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
triamcinolone acetonide
03
Conditions
otitis media with effusion (OME)
Beyond the preview
Go deeper on NCT07189572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07189572.